期刊文献+

双荧光素酶标记丙型肝炎病毒亚基因组复制子细胞模型的建立 被引量:2

Establishment of a hepatitis C virus subgenomic replicons cell model labeled with dual luciferase reporter
原文传递
导出
摘要 目的构建双荧光素酶标记丙型肝炎病毒(HCV)亚基因组复制子细胞模型,为HCV研究提供有效工具。方法通过单克隆筛选及慢病毒感染构建双荧光素酶标记的HCV亚基因组复制子细胞模型(HCV Fluc-UbiGluc)。利用荧光素酶检测、Western印迹检测鉴定细胞模型,利用IFN-α对HCV抗病毒效果评价验证细胞模型的有效性。结果筛选所得HCV亚基因组细胞克隆检测到荧光素酶活性,Western印迹检测到HCV NS5A蛋白表达。NS3/4A对黄色荧光蛋白(YFP)标记的MAVS(YFP-MAVS)切割作用使亚细胞定位发生转移。IFN-α处理后荧光素酶活性、HCV蛋白表达水平明显降低。结论该模型采用萤火虫荧光素酶报告基因指示HCV亚基因组在细胞内的复制水平,Gaussia荧光素酶指示细胞的生长数量,能准确反映候选药物对HCV复制水平的影响,并有效排除药物的细胞毒性干扰,具有操作简单、快速等优点,在抗病毒药物高通量筛选、HCV致病机制等研究方面具有一定的价值。 Objective To establish an HCV subgenomic replicons cell model that is labeled with reporter gene and to provide a useful tool for HCV research.Methods An HCV subgenomic replicons cell model [HCV-firefly luciferase(Fluc)-Ubi-Gaussia luciferase(Gluc) ]containing dual luciferase reporters was established by monoclonal selection and lentivirus infections.The reporter and HCV protein expression were confirmed by luciferase activity assay and Western blotting,respectively.The efficacy of the cell model was validated by IFN-α which was shown to inhibit HCV replication.Results Luciferase activity and HCV NS5A protein were detected by luciferase activity assay and Western blotting,respectively.Subcellular localization of yellow fluorescence protein(YFP)-MAVS was transferred from mitochondria to nucleis by cleavage of NS3 /4A protease in HCV replicons cells.HCV proteins and luciferase activity were diminished obviously after IFN-α treatment.Conclusion In this cell model,the HCV RNA and host cells are labeled with firefly luciferase and Gaussia luciferase,respectively.The mold can indicate the level of HCV replication and eliminate the cytotoxicity antivirus drugs induced effectively.It will be a valuable tool for studying HCV pathogenesis and screening antiviral drugs.
出处 《军事医学》 CAS CSCD 北大核心 2013年第9期681-684,691,共5页 Military Medical Sciences
基金 北京市自然科学基金资助项目(7112104 7122136)
关键词 丙型肝炎病毒 荧光素酶类 萤火虫 Gaussia荧光素酶 细胞模型 复制子 HCV luciferases firefly Gaussia luciferase cell model replicon
  • 相关文献

参考文献12

  • 1Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection [ J ]. Lancet Infect Dis,2005,5 (9) :558 - 567.
  • 2霍艳英,徐德忠,赵小宁,李如琳,刘蓬勃,王全楚,王歆.西安和郑州地区丙型肝炎患者的HCV基因分型[J].第四军医大学学报,2002,23(8):749-751. 被引量:84
  • 3Penin F, Dubuisson J, Rey FA, et al. Structural biology of hepati- tis C virus [ J ]. Hepatology,2004,39 ( 1 ) :5 - 19.
  • 4Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus [J]. Nat Rev Microbiol,2007,5(6) :453 - 463.
  • 5Bartenschlager R, Lohmann V. Replication of hepatitis C virus [ J ]. Gen Viro1,2000,81 ( Pt 7 ) : 1631 - 1648.
  • 6Lohmann V, Korner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line [ J ]. Science, 1999,285(5424) :110 - 113.
  • 7Bartenschlager R. The hepatitis C virus replicon system: from basic research to clinical application [ J ]. Hepatology, 2005,43 (2) :210 -216.
  • 8Bartenschlager R, Kaul A, Sparacio S. Replication of the hepatitis C virus in cell culture[J]. Antiviral Res,2003,60(2) :91 - 102.
  • 9Koutsoudakis G, Kaul A, Teinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase re- porter viruses[ J. J Viol ,2006,80 ( 11 ) :5308 - 5320.
  • 10Kim CS, Jung JH, Wakita T, et al. Monitoring the antiviral effect of alpha interferon on individual ceils [ J ]. J Virol, 2007,81 (16) :8814 -8820.

二级参考文献1

共引文献83

同被引文献20

  • 1周一炎,尚桂芳,杨立新,祁自柏,徐欣,仝文斌,伍宇.HCV核心抗原作为“窗口期”HCV感染标志物的检测[J].中国输血杂志,2004,17(3):162-163. 被引量:7
  • 2雷永良,纪勇平,吴丽雅,钟美莲,周巧珍.部分ELISA抗-HCV阴性和阳性血清丙肝抗体分片段检测分析[J].中国输血杂志,2004,17(4):252-253. 被引量:3
  • 3MIHAILARG, CIPAIAN R C.Eltrombopag in chronic hep- atitis C [J]. World J Gastroenterol,2014,20 (35):12 517- 12 521. I.
  • 4KEDA M L,ABE K,YAMADA M,et al. Different anti- HCV profiles of statins and their potential for combination therapy with interferon [J]. Hepatology,2006,44 ( 1 ): 117-125.
  • 5IKEDA M L, KATO N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon[ J ]. J Pharmacol Sci, 2007,105 (2): 145- 150.
  • 6TORRESI J,JOHNSON D,WEDEMEYER H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus [J]. J Hepatol,2011,54 (6):1 273-1 285.
  • 7Pereira FM, Sant 'ana zarife MA, Gomes reis EA, et al. Indeterminate RIBA results were associated with the ab-- sence of hepatitis C virus RNA (HCV-RNA) in blood do nors[J]. Rev Soc Bras Med Trop,2014,47(1):12-17.
  • 8Calvaruso V, Craxi A. 2011 European association of the study of the liver hepatitis C virus clinical practice guide- lines[J]. Liver Int, 2012,32 (Suppll) : 2 -8.
  • 9Mohammadali F,Pourfathollah AA. Changes in frequency of HBV,HCV, HIV and syphilis infections among blood donors in Tehran province 2005- 2011 [J]. Arch Iran Med,2014,17(9):613 -620.
  • 10Klenerman P, Gupta PK. Hepatitis C virus:current con cepts and future challenges[J].QJM, 2012,105 (1) : 29- 32.

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部